Bioavailability (animal study)
In a published animal pharmacokinetic study, LXM.5 (levodopa/carbidopa) showed more than 380% higher bioavailability than Sinemet®.
Source: Enke M, Bünger M, Aedtner E, Kastner S, Gruschwitz F, Kühne K, Czernik-Schulz D, Greeley DR, Volc D, Buzachnich-Ladinig A, Schneeberger A. Three-Dimensional Screen Printing Technology Enables Sequential Release of Carbidopa and Levodopa—A New Approach Improving Levodopa Delivery for Treating Parkinson’s Disease. Pharmaceutics. 2025;17(12), 1507. https://doi.org/10.3390/pharmaceutics17121507

